MARKET INSIGHT: Insulin delivery techs and the role of long-term cost structures
This article was originally published in Clinica
Uptake of insulin pump therapy varies sharply from market to market. In the US, over a third of Type I diabetics use a pump, but in Europe this can be as low as the mid-single digits. The speed of new technology roll-outs can be affected by the previous therapy policy of any particular country, but are stakeholders doing enough to ensure that more eligible individuals can access this proven delivery means? IBI principal analyst Ashley Yeo investigates
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?